{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T10:44:19Z","timestamp":1789641859497,"version":"4.0.0"},"reference-count":37,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2012,7,11]],"date-time":"2012-07-11T00:00:00Z","timestamp":1341964800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2013,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Topical TLR7 agonists such as imiquimod are highly effective for the treatment of dermatological malignancies; however, their efficacy in the treatment of nondermatological tumors has been less successful. We report that oral administration of the novel TLR7\u2010selective small molecule agonist; SM\u2010276001, leads to the induction of an inflammatory cytokine and chemokine milieu and to the activation of a diverse population of immune effector cells including T and B lymphocytes, NK and NKT cells. Oral administration of SM\u2010276001 leads to the induction of IFN\u03b1, TNF\u03b1 and IL\u201012p40 and a reduction in tumor burden in the Balb\/c syngeneic Renca and CT26 models. Using the OV2944\u2010HM\u20101 model of ovarian cancer which spontaneously metastasizes to the lungs following subcutaneous implantation, we evaluated the efficacy of intratracheal and oral administration of SM\u2010276001 in an adjuvant setting following surgical resection of the primary tumor. We show that both oral and intratracheal TLR7 therapy can reduce the frequency of pulmonary metastasis, and metastasis to the axillary lymph nodes. These results demonstrate that SM\u2010276001 is a potent selective TLR7 agonist that can induce antitumor immune responses when dosed either intratracheally or orally.<\/jats:p>","DOI":"10.1002\/ijc.27691","type":"journal-article","created":{"date-parts":[[2012,6,26]],"date-time":"2012-06-26T14:29:37Z","timestamp":1340720977000},"page":"580-590","source":"Crossref","is-referenced-by-count":25,"title":["Intratracheal and oral administration of SM\u2010276001: A selective TLR7 agonist, leads to antitumor efficacy in primary and metastatic models of cancer"],"prefix":"10.1002","volume":"132","author":[{"given":"Erina","family":"Koga\u2010Yamakawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon J.","family":"Dovedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Murata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Leishman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon P.","family":"Heaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Oki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Tomizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ash","family":"Bahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruo","family":"Takaku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Wilkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,7,11]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.6.3472"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2009.03173.x"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.3109\/15476910903286733"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1443"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.3.1178"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1586"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.8.4102"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/ni758"},{"key":"e_1_2_6_10_2","first-page":"re4","article-title":"The role of the kinases RIP1 and RIP3 in TNF\u2010induced necrosis","volume":"3","author":"Vandenabeele P","journal-title":"Sci Signal"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.2.767"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0631696100"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M311618200"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210913"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.3.1259"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0803826"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-238543"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M312219200"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.189.9.1451"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2008-0097"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(99)70261-6"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm051089s"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.38.2.681-685.1982"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-09-1198"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.1989.tb02336.x"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3181587d29"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-009-0983-z"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)03544-2"},{"key":"e_1_2_6_29_2","first-page":"1678","article-title":"Phase I trial of twice\u2010weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN\u2010gamma induction is associated with clinical response","volume":"6","author":"Gollob JA","year":"2000","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-348839"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1622"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.9793"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-1782"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2008.91"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04745.x"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2011.02.092"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200908-1255OC"},{"key":"e_1_2_6_38_2","first-page":"3548","article-title":"Antitumor activity of a synthetic agonist of TLR9 administered via intranasal route","volume":"2007","author":"Wang D","year":"2007","journal-title":"AACR Meet Abstr"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.27691","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.27691","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T12:15:44Z","timestamp":1697458544000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.27691"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,11]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["10.1002\/ijc.27691"],"URL":"https:\/\/doi.org\/10.1002\/ijc.27691","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,11]]}}}